NTRK1 and cancer: For the treatment of NTRK-rearranged cancer, multiple TRK inhibitors are under clinical evaluation, and larotrectinib and entrectinib have shown clinical efficacy in clinical trials, and larotrectinib was recently approved by US-FDA.